期刊文献+

奥沙利铂联合多西紫杉醇治疗晚期非小细胞肺癌的临床观察

Clinical Observation of Docetaxel and Oxaliplatin on Advanced Non-small Cell Lung Cancer
下载PDF
导出
摘要 目的:观察奥沙利铂联合多西紫杉醇治疗晚期非小细胞肺癌的临床疗效及不良反应。方法:将晚期非小细胞肺癌患者68例随机分为两组,观察组34例采用奥沙利铂联合多西紫杉醇治疗,对照组34例采用顺铂联合多西紫杉醇治疗,进行疗效及不良反应比较观察,所有患者完成2个周期用药。结果:观察组总有效率(CR+PR)为47.1%,对照组总有效率(CR+PR)为41.2%,两组比较差异无统计学意义(P>0.05)。观察组恶心呕吐明显低于对照组(P<0.05)。结论:对于晚期非小细胞肺癌患者,使用奥沙利铂联合多西紫杉醇与使用顺铂联合多西紫杉醇进行比较,疗效相似,但使用奥沙利铂能有效改善患者的临床症状,副反应较轻,是值得临床推广的化疗方案。 Objective: To observe clinical efficacy and adverse reactions of advanced non-small cell lung cancer by docetaxel and oxaliplatin.Method: 68 cases of non-small cell lung cancer patients were randomly divided into two groups.Observation group(34 cases) treated by docetaxe[ combined with oxaliplatin, control group(34 cases) treated with cisplatin combined with docetaxel, comparing curative effect observation.All the patients completed 2 cycles of drug using. Result: Observation group total effective rate(CR+PR) was 47.1%, control group total effective rate(CR+PR) was 41.2%, there was no statistically significant difference(P〉0.05).Adverse reactions in two groups, nausea and vomiting observation group was obviously lower than the control group(P〈0.05).Conclnsion: For advanced non-small cell lung cancer patients, the use of oxaliplatin into joint docetaxel group and use cisplatin plus docetaxel group, curative effect is similar, but the use of oxaliplatin into group can effectively improve the patient' s clinical symptoms, the adverse event is lighter, is worthy of clinical promotion chemotherapy regimens.
作者 魏蓉 李勤
出处 《中外医学研究》 2013年第28期1-3,共3页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 奥沙利铂 多西紫杉醇 顺铂 非小细胞肺癌 Oxaliplatin Docetaxel Cisplatin Non-small cell lung cancer
  • 相关文献

参考文献5

二级参考文献19

  • 1王凤庭,郑红霞.多西紫杉醇联合顺铂治疗晚期非小细胞肺癌32例疗效观察[J].现代肿瘤医学,2007,15(1):40-41. 被引量:2
  • 2Jemal A Murray T,Samuels A,et al.Cancer statistics 2002[J].Cane-er J Clin ,2003,53:5. 被引量:1
  • 3周际昌.实用肿瘤内科学[M].2版.北京:人民卫生出版社,2005:28. 被引量:1
  • 4Ganders DR,Lam PN Jr,Goldberg Z,et al. Neoadjuvant therapy fornon-small cell lung cancer[J].Anticancer Drugs, 2001,12 : 5. 被引量:1
  • 5周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,2005:601~610. 被引量:150
  • 6Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimen for advanced non - small cell lung cancer [J]. N Engl J Med,2002,346(2) :92 -98. 被引量:1
  • 7曹克明.肿瘤药物手册[M].上海:第二军医大学出版社,2003:131-132. 被引量:1
  • 8Fossella FV, Lee JS, Kau SW, et al. Docetaxel for platinum refractory non -small cell lung cancer: Comparison of phase H results to historical control [ J ]. Proc Am Soc Clin Oncol, 1997,16 (2) :468. 被引量:1
  • 9Non-small cell lung cancer collabortive group.Chemotherapy in non small cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomised clinical trials[J].BMJ,1995,311(1):899-909. 被引量:1
  • 10Schiller J H,Harrington D,Belani C P,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N EngI J Med,2002,346(2):92-98. 被引量:1

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部